必可酮配伍思密达防治放射性口腔炎的临床观察

目的 观察必可酮配伍思密达防治放射性口腔炎的疗效。方法 88例头颈部肿瘤放疗患者随机分成治疗组与对照组各44例，治疗组采用必可酮配伍思密达，对照组采用朵贝氏液及VitB1治疗。结果 治疗组口腔炎发生率38．6％，对照组为59．1％；治疗组3、4级口腔炎发生率为6．8％，二者均有统计学差异（P＜0．01）。结论 必可酮配伍思密达是防治放射性口腔炎的一种有效方法。     

口含碳酸氢钠冰块及小牛血去蛋白提取物防治头颈部肿瘤放射性口腔炎的临床观察

目的：观察碳酸氢钠冰块和小牛血去蛋白提取物联合应用对头颈部放射性口腔炎的防治效果。方法：对2009年2月-2010年10月住院放疗的头颈部肿瘤患者60例,随机分为对照组和治疗组,每组各30例。对照组采用常规口腔护理,治疗组在常规口腔护理的基础上加用碳酸氢钠冰块含化和小牛血去蛋白提取物超声雾化吸入,自放疗开始后每天2次,每次20 min。结果：治疗组口腔黏膜急性放射损伤较对照组明显减轻（P〈0.01）。结论：口含碳酸氢钠冰块及小牛血去蛋白提取物超声雾化用于防治放疗后放射性口腔黏膜炎,能降低其发生率,减轻黏膜炎严重程度,延缓其进展。     

口炎清颗粒防治鼻咽癌患者放射性口腔炎的疗效观察

目的 观察口炎清颗粒对鼻咽癌患者放射性口腔炎的防治效果。方法 将60例鼻咽癌行适形调强放疗患者随机分为2组,口炎清组（30例）于放射治疗开始给予口炎清颗粒口服至放射治疗结束,对照组（30例）在放射治疗过程中出现2级及以上放射性口腔黏膜炎时,给予0.9%氯化钠注射液、利多卡因、地塞米松、维生素B12与维生素B2配制成漱口液含漱。采用全美放射肿瘤治疗协作组急性放射性黏膜炎的分级标准比较2组患者放射性口腔炎发生的时间、程度以及疼痛分级情况。结果 口炎清组和对照组放射性口腔炎出现的时间分别为（12.40±2.74）、（9.46±1.39） d,二者间差异有统计学意义（t=5.241,P<0.001）。口炎清组患者的疼痛分级、放射性口腔炎的分级比较均明显低于对照组,差异有统计学意义。结论 口炎清颗粒可延迟放射性口腔炎的发生时间,降低放射性口腔炎的严重程度,减轻患者疼痛,改善患者临床症状,有效防治鼻咽癌放疗引起的放射性口腔炎。     

中药含服液防治放射性口腔炎的疗效观察

目的评价中医药防治放射性口腔炎的疗效。方法将134例鼻咽癌放疗后出现口腔黏膜炎的患者随机分成两组，以金银花、玄参、水牛角、麦冬等中药制剂含服治疗患者为实验组，复方硼砂溶液含漱治疗的患者作为对照组，按WHO放射性口腔黏膜反应标准记录患者的口腔黏膜炎程度。结果中药含服液治疗67例，出现Ⅰ、Ⅱ、Ⅲ、Ⅳ级口腔黏膜炎分别为37、21、6、3例：对照组67例，出现Ⅰ、Ⅱ、Ⅲ、Ⅳ级口腔黏膜炎分别为4、26、28、9例；两组比较差异具有显著性（P〈0．01）。结论中药含服液防治放射性口腔炎具有独特的疗效。     

“新净界漱口水”对放射性口腔黏膜炎的防治效果观察

目的： 前瞻性随机双盲研究“新净界漱口水”对放射性口腔黏膜炎的防治效果。方法：60例拟行放疗的口腔癌患者随机分为试验组和对照组;试验组30例,自放疗第1天起,每天使用“新净界漱口水”含漱4次,每次5 mL,含漱 5 min,直至放疗结束。对照组30例使用生理盐水含漱,方法同试验组。按RTOG口腔黏膜炎分级标准评价2组患者的口腔黏膜炎严重程度,记录疼痛程度,并照相存档。3级口腔黏膜炎视为终止指标,发生者给予其他药物治疗。应用Stata 12.0软件包对数据进行统计分析。结果：2组患者的年龄、性别、放疗技术和剂量无显著差异（P>0.05）。试验组首次观察到黏膜炎的发生时间较对照组晚（照射11.0次∶9.1次,P<0.05）,且试验组在早期出现疼痛的比例较对照组低（36.7%∶70.0%,P<0.05）。另外,试验组3级口腔黏膜炎的出现时间较对照组晚（照射18.9次∶15.9次,P<0.05）,发生率较对照组低（63.3%∶90.0%,P<0.05）。结论：“新净界漱口水”能延缓放疗所致口腔黏膜炎的发生时间,减轻患者的疼痛症状,并能减少3级口腔黏膜炎的发生率,值得临床使用。     

头颈部恶性肿瘤患者放疗前外周血淋巴细胞核内γ-H2AX焦点数与放疗后急性放射性损伤程度相关性研究

目的 探讨头颈部恶性肿瘤患者放疗前外周血淋巴细胞核内γ-H2AX焦点数与放疗后急性放射性黏膜和皮肤反应程度的相关性。方法 选择2010年12月至2012年3月湖北三峡职业技术学院附属医院收治的34例头颈部恶性肿瘤初诊患者,采集其外周血进行1Gy的6MV-X线照射,通过细胞免疫荧光技术检测淋巴细胞核内γ-H2AX焦点数;同时追踪观察所有患者放疗后出现急性放射性黏膜和皮肤反应的情况,探寻其与外周血淋巴细胞核内γ-H2AX焦点数之间的相关性。结果 34例患者中,出现急性放射性黏膜反应Ⅰ级6例（占17.65%）,Ⅱ级19例（占55.88%）,Ⅲ级8例（占23.53%）,Ⅳ级1例（占2.94%）;出现急性放射性皮肤损伤Ⅰ级9例（占26.47%）,Ⅱ级12例（占35.29%）,Ⅲ级13例（占38.24%）。急性放射性黏膜和皮肤反应程度与患者外周血淋巴细胞核内γ-H2AX焦点数的水平均呈正相关（r = 0.815,P < 0.05;r = 0.888,P < 0.05）。结论 头颈部恶性肿瘤患者放疗前检测外周血淋巴细胞核内γ-H2AX焦点数的水平可作为预测放疗后急性放射性黏膜和皮肤反应发生风险大小及严重程度的客观生物学指标。     

贝复济防治放射性口腔黏膜炎的疗效观察

目的：头颈部放疗过程中采用贝复济防治黏膜炎,动态观察黏膜炎的发生发展情况,探求更有效的防治方法。方法：40例头颈部放疗患者分为实验组和对照组,实验组患者采用贝复济喷剂合并碳酸氢钠溶液含漱,对照组患者采用碳酸氢钠溶液漱口。放疗前后5次记录黏膜炎的变化。结果：黏膜炎在放疗早期即可发生,随着放疗剂量的增加而逐渐加重,放疗停止后黏膜炎症状较快消退;实验组黏膜炎的发生例数和严重程度较低,较对照组有显著性差异。结论：黏膜炎是不可避免、可逆的损伤。做好放疗患者的口腔卫生指导及防护,采用贝复济合并碳酸氢钠含漱防治放射性黏膜炎,可降低黏膜炎的发病率和严重程度,提高病人的生活质量。     

思密达治疗复发性口疮临床对比研究

目的：比较思密达和金因肽治疗复发性口疮的疗效。方法：复发性口疮94例随机分成三组,思密达组,金因肽组、对照组．思密达组（32例）,用思密达糊剂外涂．金因肽组（32例）用金因肽喷涂,对照组（30例）不用外用药物。短期疗效;观察疼痛程度、充血程度、溃疡最大直径的改变、溃疡愈合时间。治疗1年内的短期疗效,治疗后半年内的长期疗效：观察无溃疡时间（天）总和（I）,溃疡数目总和（N）。结果：短期疗效：同对照组相比思密达组、金因肽组疼痛程度显著减轻、充血程度显著减轻、溃疡最大直径显著减小,溃疡愈合时间缩短。有统计学差异（P〈0．0．5）。同对照组相比思密达组、金因肽组总有效率高,与对照组比较有统计学差异（尸〈0．0．5）。金因肽组与思密达组相比疼痛程度减轻、充血程度减轻、溃疡最大直径缩小,溃疡愈合时间缩短,但无统计学差异（尸〉0．05）。金因肽组与思密达组比较总有效率高,但无统计学差异（P〉0．05）。治疗1年内的短期疗效,治疗后半年内的长期疗效：思密达组和金因肽组总间歇时间（d）、总溃疡数比较,无统计学差异（P〉0．05）。两组总间歇时间（d）与对照组比较,有统计学差异（P〈0．0．5）。两组总溃疡数（个）与对照组比较。无统计学差异（P〉O．05）。结论：思密达具有较好的临床疗效,长期应用思密达可延长溃疡间歇期．。     

可调式口腔矫治器治疗儿童阻塞性睡眠呼吸暂停综合征的临床研究

目的：评价可调式口腔矫治器治疗儿童阻塞性睡眠呼吸暂停综合征（OSAS）的疗效。方法：45例OSAS患儿,采用多导睡眠仪监测戴用可调式口腔矫治器前后多项指标变化如：呼吸紊乱指数（AHI）,呼吸暂停指数（AI）,最低sao2和睡眠效率等指标并进行分析。结果：45例OSAS患儿AHI有效率（P〈0.01）：10例轻度患儿为66.7%,23例中度患儿为62.1%,12例重度患儿67.9%。AI有效率（P〈0.01）：10例轻度患儿为61.5%,23例中度患儿有效率为69.6%,12例重度68.4%。最低sao2显著升高（P〈0.01）：10例轻度患儿升高2.6%,23例中度患儿升高8.5%,12例重度患儿16.5%。睡眠效率升高（P〈0.01）：10例轻度患儿升高19.4%,23例中度患儿升高19.9%,12例重度患儿45.6%。患者睡眠质量均有显著改善,鼾声消失或明显减轻。结论：可调式口腔矫治器治疗儿童阻塞性睡眠呼吸暂停综合征（OSAS）疗效明显。     

爱维治防治急性放射性口咽黏膜损伤的临床研究

目的:观察爱维治(小牛血去蛋白提取物)防治急性放射性黏膜损伤的疗效。方法:35例头颈部肿瘤术后患者,随机分成2组:治疗组(17例),对照组(18例)。治疗组予常规口腔护理,同时全疗程静滴爱维治;对照组予常规口腔护理,出现黏膜损伤后静滴维生素。根据RGOT急性放射性黏膜损伤分级标准及疼痛的VAS评分进行临床评价,观察急性口咽黏膜损伤出现时间、程度及药物不良反应。结果:2组患者均发生程度不等的急性放射性黏膜损伤;2组间黏膜损伤出现的时间比较差异有显著性(P=0.0002);治疗组以Ⅰ、Ⅱ级口咽黏膜损伤为主(76.5%),对照组以Ⅲ、Ⅳ级的损伤为主(61.1%),2组间比较差异均有显著性(P=0.0409);治疗组以轻度疼痛为主(VAS评分0~3分,70.6%),对照组以中度疼痛为主(VAS评分4~6分,61.1%),2组间比较差异均有显著性(P=0.0067);对照组放疗中断的病例较多,但2组比较无显著性(P=0.3377);未见药物不良反应。结论:爱维治可推迟放射性黏膜损伤的发生,并降低Ⅲ、Ⅳ级黏膜损伤的发生率。     

爱维治对放疗所致急性口腔黏膜炎的疗效观察

目的:探讨爱维治对放疗患者急性口腔黏膜炎的临床效果及对炎性因子水平的影响.方法 :选取青海省第五人民医院肿瘤科2015 年7 月-2017 年9 月收治的113 例鼻咽癌放疗所致急性口腔黏膜炎患者,采用随机数字表法分为实验组(57 例)、对照组(56 例),实验组采用爱维治治疗.对照组采用康复新治疗,对比2 组患者治疗...     

康复新液治疗口腔鳞癌患者平阳霉素诱导化疗后口腔黏膜炎的疗效分析

目的 观察康复新液治疗口腔鳞癌患者平阳霉素诱导化疗后口腔黏膜炎的疗效。方法 将106例经平阳霉素诱导化疗后出现口腔黏膜炎的口腔鳞癌患者随机分为试验组（53例）和对照组（53例）,试验组给予康复新液含服,对照组给予口服维生素B₂和维生素C。根据口腔黏膜炎分级和疼痛程度对两组患者疗效进行对比。结果 试验组治疗口腔鳞癌患者平阳霉素诱导化疗导致的口腔黏膜炎疗效优于对照组（P<0.05）。结论 当口腔鳞癌患者经平阳霉素诱导化疗后出现口腔黏膜炎时,康复新液可有效降低其炎症程度的分级,缓解疼痛,值得推广。     

The effectiveness of vitamin "E" in the treatment of oral mucositis in children receiving chemotherapy

The aim of this study was to study the effect of vitamin "E" in the treatment of oral mucositis. 80 patients with oral mucositis were randomly distributed into 2 groups: group A, topically applied vitamin "E" and group B, vitamin "E" was given systemically. The 2 groups were evaluated for 5 days. Results showed that in group A grades of oral mucositis improved significantly, while in group B no significant improvement was noticed. It is concluded that topical application of 100 mg vitamin "E" twice daily is an effective measure for the treatment of chemotherapy-induced oral mucositis.     

Effectiveness of a comprehensive oral management protocol for the prevention of severe oral mucositis in patients receiving radiotherapy with or without chemotherapy for oral cancer: a multicentre,phase II,randomized controlled trial

The aim of this phase II, multicentre, randomized controlled trial was to evaluate the effectiveness of a comprehensive oral management protocol for the prevention of severe oral mucositis in patients with oral cancer receiving radiotherapy alone or chemoradiotherapy. In total, 124 patients with oral cancer were enrolled from five institutions. Of these, 37 patients undergoing radiotherapy were randomly divided into an intervention group (n = 18) and a control group (n = 19). The remaining 87 patients, who were undergoing chemoradiotherapy, were also randomized into an intervention group (n = 42) and a control group (n = 45). During radiotherapy, patients in the control group received only oral care, while those in the intervention group additionally received spacers to cover the entire dentition, pilocarpine hydrochloride, and topical dexamethasone ointment for oral mucositis. The primary endpoint was the incidence of severe oral mucositis. The intervention was significantly associated with a decreased incidence of severe oral mucositis in patients receiving radiotherapy alone (P = 0.046), but not in those receiving chemoradiotherapy (P = 0.815). These findings suggest that an oral management protocol can prevent severe oral mucositis in patients with oral cancer undergoing radiotherapy without concurrent chemotherapy.     

Management of oral mucositis during local radiation and systemic chemotherapy: a study of 98 patients.

Oral mucositis is among the complications of head and neck irradiation and systemic chemotherapy. To determine whether or not mucositis could be prevented or reduced in intensity by using Kamillosan Liquidum as an oral rinse, 98 patients were placed on study protocols. Twenty patients who were treated with radiation therapy and 46 patients who received systemic chemotherapy participated in prophylactic oral care with Kamillosan oral rinse. Thirty-two patients were treated therapeutically after mucositis had developed. Sixteen patients receiving chemotherapy were treated therapeutically and prophylactically with Kamillosan oral rinse during repeated cycles of chemotherapy. Only one of the 20 patients who had had radiation therapy developed grade 3 mucositis in the final week of treatment. Thirty-six of the 46 patients undergoing chemotherapy did not develop clinically noticeable mucositis. It appears that resolution of mucositis is accelerated by Kamillosan rinse. Prophylactic oral care appeared to modify the oral environment favorably and maintain tissue integrity.     

Photobiomodulation with low-level laser therapy reduces oral mucositis caused by head and neck radio-chemotherapy: prospective randomized controlled trial

The objective of this study was to assess the effectiveness of photobiomodulation with low-level laser therapy (LLLT) as a preventive and therapeutic procedure for the treatment of oral and oropharyngeal mucositis caused by radio-chemotherapy in patients diagnosed with oral squamous cell carcinoma (SCC). An experimental, prospective, double-blind, randomized controlled study was conducted involving patients diagnosed with oral SCC undergoing oncological treatment. The variables analyzed included grade, appearance, and remission of mucositis. A final sample of 26 patients was included: 11 (42.3%) in the study group and 15 (57.7%) in the control group; their average age was 60.89 ± 9.99 years. Statistically significant differences between the groups were observed from week 5 of oncological treatment; 72.7% of the laser group showed normal mucosa (mucositis grade 0), while in the control group, 20.0% showed grade 0 mucositis and 40.0% showed grade 2 mucositis (P < 0.01). No statistically significant difference between the groups was found regarding the application or use of medication throughout the study period (P > 0.05). The tolerance evaluation did not show any statistically significant difference between the groups regarding the occurrence of side effects or adverse events during the trial (P > 0.05). Photobiomodulation with LLLT reduces the incidence and severity of mucositis in patients treated with radiotherapy ± chemotherapy.     

低能量激光照射治疗对肿瘤患者放化疗后口腔黏膜炎的疗效观察

目的：观察低能量激光照射治疗对肿瘤患者放化疗后口腔黏膜炎的预防作用。方法：肿瘤科放化疗患者60例,用数字随机表法随机分为实验组（n＝30）和对照组（n＝30）,两组患者放化疗方案根据肿瘤科方案进行,口腔护理采用相同的标准进行,实验组进行低能量激光照射,每天1次,每周5次,对照组无低能量激光照射,两组患者分别与实验开始后1、2、3、4周由口腔医师检查患者口腔黏膜炎严重程度及疼痛程度,进行评定。结果：实验组患者口腔黏膜炎的严重程度和疼痛程度较对照组明显降低,口腔黏膜炎3级、4级发生率两组间差异均有统计学意义。结论：低能量激光照射对肿瘤患者放化疗后的口腔黏膜炎具有明显的预防作用。